FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978342037> ?p ?o ?g. }

• W2978342037 endingPage "v164" @default.
• W2978342037 startingPage "v164" @default.
• W2978342037 abstract "Abstract Background MEK inhibitors (MEKi) lack single agent clinical efficacy in RAS mutant cancers, likely because MEKi produce only a cytostatic response in preclinical RAS mutant cancer models. BCL-XL is an anti-apoptotic BCL2 family protein identified by a synthetic lethal shRNA screen as a key suppressor of apoptotic response to MEKi. BCL-XL was found to bind and inhibit BIM, the key pro-apoptotic protein induced by MEKi. Combined BCL-XL/MEK inhibition led to tumor regressions in mouse models of RAS mutant cancers. Methods In dose escalation, N (150, 200, 250, 300mg daily) was given d1-28 (after a 7d lead at 150mg daily). T (1, 1.5, 2mg daily) was given d1-28 in schedules A and B, or d1-14 only of a 28d cycle in schedule C. Pre-treatment and d15 on-treatment biopsies and serial cell-free (cf)DNA were obtained. Results To date, 43 patients (pts) (median age 60) initiated treatment (A [n = 9]; B [n = 11]; C [n = 23]), 38 in dose escalation; 66.7% had ≥4 prior therapies. 9/43 (20.9%) had colorectal cancer (CRC), 8/43 (18.6%) pancreatic, 9/43 (20.9%) NSCLC and 11/43 (25.6%) gynecologic (GYN) cancers. 14/43 (32.6%) were KRAS G12D, 7/43 (16.3%) G12C, 7/43 (16.3%) G12V.Recommended phase 2 dose (RP2D) was established as T 2mg d1-14 + N 250mg d1-28.Gr 3-4 treatment related AEs occurred in 40% pts, with AST increase, diarrhea, decreased platelets most common. At RP2D, 2/13 evaluable pts had confirmed PR (15.4%) with disease control rate (DCR; PR + SD) 46.2%. Early potential disease-specific differences in efficacy were noted. In GYN pts at all doses, overall DCR = 63.6%, with 2/11 (18.1%) with ongoing confirmed PR (-60% and -51% by RECIST), including one >20 mos. By contrast no PRs were seen in 9 CRC pts, with overall DCR only 22%. Evidence of MAPK pathway inhibition was observed in on-treatment tumor biopsies. Pts with PR/SD had a median decrease in mutant KRAS levels in cfDNA of 64% by 4 wks. Conclusions Combination of N+T was tolerable, and R2PD was established. Initial signs of efficacy were noted, with favorable DCR and durable PRs in RAS mutant GYN pts. Expansion cohorts are currently enrolling in GYN, NSCLC, pancreatic pts, and NRAS mutant cancers. Updated efficacy and correlative data will be presented. Clinical trial identification NCT02079740. Legal entity responsible for the study NCI/CTEP. Funding NCI/CTEP. Disclosure R.B. Corcoran: Honoraria (self): Array Biopharma; Honoraria (self): Astex Pharmaceuticals; Honoraria (self): BMS; Honoraria (self): FOG Pharma; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Fount Therapeutics; Honoraria (self): N-of-one; Honoraria (self): Revolution Medicines; Advisory / Consultancy, Shareholder / Stockholder / Stock options: nRichDx; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Avidity Biosciences; Honoraria (self): Novartis; Honoraria (self): Taiho. L.G. Ahronian: Full / Part-time employment: Tango Therapeutics. All other authors have declared no conflicts of interest." @default.
• W2978342037 created "2019-10-10" @default.
• W2978342037 creator A5002656220 @default.
• W2978342037 creator A5008479799 @default.
• W2978342037 creator A5018251973 @default.
• W2978342037 creator A5018655814 @default.
• W2978342037 creator A5025652849 @default.
• W2978342037 creator A5026482426 @default.
• W2978342037 creator A5029140460 @default.
• W2978342037 creator A5030510204 @default.
• W2978342037 creator A5042460988 @default.
• W2978342037 creator A5052640502 @default.
• W2978342037 creator A5055358118 @default.
• W2978342037 creator A5064382279 @default.
• W2978342037 creator A5064958509 @default.
• W2978342037 creator A5067275862 @default.
• W2978342037 creator A5076412077 @default.
• W2978342037 creator A5077582595 @default.
• W2978342037 creator A5087305091 @default.
• W2978342037 creator A5087308492 @default.
• W2978342037 creator A5088942244 @default.
• W2978342037 date "2019-10-01" @default.
• W2978342037 modified "2023-09-27" @default.
• W2978342037 title "Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours" @default.
• W2978342037 doi "https://doi.org/10.1093/annonc/mdz244.009" @default.
• W2978342037 hasPublicationYear "2019" @default.
• W2978342037 type Work @default.
• W2978342037 sameAs 2978342037 @default.
• W2978342037 citedByCount "13" @default.
• W2978342037 countsByYear W29783420372021 @default.
• W2978342037 countsByYear W29783420372022 @default.
• W2978342037 countsByYear W29783420372023 @default.
• W2978342037 crossrefType "journal-article" @default.
• W2978342037 hasAuthorship W2978342037A5002656220 @default.
• W2978342037 hasAuthorship W2978342037A5008479799 @default.
• W2978342037 hasAuthorship W2978342037A5018251973 @default.
• W2978342037 hasAuthorship W2978342037A5018655814 @default.
• W2978342037 hasAuthorship W2978342037A5025652849 @default.
• W2978342037 hasAuthorship W2978342037A5026482426 @default.
• W2978342037 hasAuthorship W2978342037A5029140460 @default.
• W2978342037 hasAuthorship W2978342037A5030510204 @default.
• W2978342037 hasAuthorship W2978342037A5042460988 @default.
• W2978342037 hasAuthorship W2978342037A5052640502 @default.
• W2978342037 hasAuthorship W2978342037A5055358118 @default.
• W2978342037 hasAuthorship W2978342037A5064382279 @default.
• W2978342037 hasAuthorship W2978342037A5064958509 @default.
• W2978342037 hasAuthorship W2978342037A5067275862 @default.
• W2978342037 hasAuthorship W2978342037A5076412077 @default.
• W2978342037 hasAuthorship W2978342037A5077582595 @default.
• W2978342037 hasAuthorship W2978342037A5087305091 @default.
• W2978342037 hasAuthorship W2978342037A5087308492 @default.
• W2978342037 hasAuthorship W2978342037A5088942244 @default.
• W2978342037 hasBestOaLocation W29783420371 @default.
• W2978342037 hasConcept C104317684 @default.
• W2978342037 hasConcept C121608353 @default.
• W2978342037 hasConcept C126322002 @default.
• W2978342037 hasConcept C143065580 @default.
• W2978342037 hasConcept C184235292 @default.
• W2978342037 hasConcept C21790070 @default.
• W2978342037 hasConcept C2778472372 @default.
• W2978342037 hasConcept C2781187634 @default.
• W2978342037 hasConcept C2781249067 @default.
• W2978342037 hasConcept C502942594 @default.
• W2978342037 hasConcept C526805850 @default.
• W2978342037 hasConcept C54355233 @default.
• W2978342037 hasConcept C57074206 @default.
• W2978342037 hasConcept C71924100 @default.
• W2978342037 hasConcept C86803240 @default.
• W2978342037 hasConceptScore W2978342037C104317684 @default.
• W2978342037 hasConceptScore W2978342037C121608353 @default.
• W2978342037 hasConceptScore W2978342037C126322002 @default.
• W2978342037 hasConceptScore W2978342037C143065580 @default.
• W2978342037 hasConceptScore W2978342037C184235292 @default.
• W2978342037 hasConceptScore W2978342037C21790070 @default.
• W2978342037 hasConceptScore W2978342037C2778472372 @default.
• W2978342037 hasConceptScore W2978342037C2781187634 @default.
• W2978342037 hasConceptScore W2978342037C2781249067 @default.
• W2978342037 hasConceptScore W2978342037C502942594 @default.
• W2978342037 hasConceptScore W2978342037C526805850 @default.
• W2978342037 hasConceptScore W2978342037C54355233 @default.
• W2978342037 hasConceptScore W2978342037C57074206 @default.
• W2978342037 hasConceptScore W2978342037C71924100 @default.
• W2978342037 hasConceptScore W2978342037C86803240 @default.
• W2978342037 hasLocation W29783420371 @default.
• W2978342037 hasOpenAccess W2978342037 @default.
• W2978342037 hasPrimaryLocation W29783420371 @default.
• W2978342037 hasRelatedWork W1560634350 @default.
• W2978342037 hasRelatedWork W1984623460 @default.
• W2978342037 hasRelatedWork W2261929084 @default.
• W2978342037 hasRelatedWork W2741536934 @default.
• W2978342037 hasRelatedWork W2897682253 @default.
• W2978342037 hasRelatedWork W2920147611 @default.
• W2978342037 hasRelatedWork W2995994395 @default.
• W2978342037 hasRelatedWork W3022164378 @default.
• W2978342037 hasRelatedWork W3083660934 @default.
• W2978342037 hasRelatedWork W4308447204 @default.
• W2978342037 hasVolume "30" @default.
• W2978342037 isParatext "false" @default.

• next